




Michael Cymbor, OD, FAAO
COPE 98001-TD

Retina Update

1

Disclosure Dr. Cymbor

- Key opinion leader and/or speaker for:
 - Visionix (Optovue)
 - Quidel
 - New World Medical
 - LKC Technologies
 - Allergan
 - Tarsus
 - Topcon
 - Thea

All financial relationships have been mitigated

2

Ways to reach out


mcymbor@nittanyeye.com





MIKECYMBOR.COM

3



Fred H. Carlin,
O.D. Community
Vision Foundation

- www.fhcvision.org


4

Case

- 46 Y/O W/F
- Type 2 Diabetes x 5 years, HTN x 5 years
 - Metformin
 - Last A1C 6.8
- No previous retinopathy
- BP 162/92 RAS
- LDL-C 160mg/dL
- Reports little to no exercise

5

Retinopathy?




6

Do you...

Tell her that she has no signs of retinopathy, keep doing what she's doing and see her in a year?

7

Or do you...



8

Or do you...

1

Diagnose her with hypertensive and diabetic retinopathy/retinal ischemia

2

Explain that her BP and A1C are too high and contact PCP

3

Recommend that she be on cholesterol meds

4

Recommend an exercise program

5

Consider diabetic nutraceutical supplementation and electronic blood sugar monitoring

9

Interventional Management


Glaucoma

Diabetic Retinopathy?

10

In the Management of Diabetic Retinopathy

- When is the right time to refer to retina?




11


Case

- 59 Y/O W/F
- Last year's exam – mild nonproliferative diabetic retinopathy OU
- Reports fluctuating blood sugars, last A1C 8.1
- BP 147/93 RAS
- Last LDL-C was 163
- Little to no exercise
- Vision seems different
- BCVA 20/20 OD and OS
- NS1


12




13




14




15




16




17




18




19




20




21



22



23



24

Downgrade to moderate nonproliferative diabetic retinopathy

- 1 Discuss with PCP
- 2 Start walking program
- 3 Begin diabetic supplements
- 4 Discuss mediterranean diet
- 5 Recommend more aggressive HTN and cholesterol management


25

Case

- 46 Y/O H/M
- Exam 1 year ago with moderate nonproliferative diabetic retinopathy
- On metformin and glipizide
- Reports borderline high cholesterol at last PCP visit, BP today 152/93
- BCVA 20/20 OD and OS
- Mac OCT below 300 microns




26




27

OCT-A



28

ERG



29

OD Coder



- 92273 Full field electroretinogram for diabetes
- 92274 Multifocal electroretinogram
- \$118.32
- Written order, Interpretation and report
- Any diabetic retinopathy code
- Changes in retinal vascular appearance H35.011-013
- Hypertensive retinopathy H35.031-033
- Retinal ischemia H35.82




30

Diagnosis

- Still moderate non-proliferative
- But dangerously close to the 23.5 threshold
- If ERG DR score is greater than 23.5 then **34%** chance of needing ocular intervention
- If less than 23.5 then **3%** chance of needing ocular intervention

31

Management



32

The Issue of Supplementation



33

2 diabetes supplements

- 1) Nuretin (PRN)
 - In this study, at 24 months, the difference between groups in the decrease of central subfield macular thickness was significant in favor of the DHA supplementation group and gains of >5 and >10 letters were significantly higher in the DHA supplementation group as compared with controls.
 - Lafuente, Maria, et al. "COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHExAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA." *Retina*, vol. 37, no. 7, July 2017, pp. 1277–1286.
- 2) DVS Formula (EyePromise)
 - Participants in the DVS group showed a statistically significant improvement in visual acuity compared to the placebo group, a reduction in retinal thickness indicating a decrease in macular edema and the progression of diabetic retinopathy was significantly slower in the DVS group compared to the placebo group.
 - Chiquet-EP, Reicher SP, Gertsen JD, Kowalski RA. The Diabetes Visual Function Supplement Study (DVS-FES). *Br J Ophthalmol*. 2016 Feb;100(2):227-34. doi: 10.1136/bjophthalmol-2014-306534. Epub 2015 Jun 18. PMID: 26089230; PMCID: PMC4752638.



34

Case

63 Y/O W/M, reports little to no exercise

HA1C 8.1

On Toujeo (insulin)

Recently started taking Ozempic, Jardiance

OchTx moderate NPDR, Hypertensive retinopathy, Chronic Angle closure glaucoma - mild, YAG PI 2020 OU, SLT 2020 OU

IOP 21.2mmHg OD and 23.3 mmHg OS

35

Are you asking about HA1C?

Is there a better metric?




36

Time in Range



People With Diabetes


Type 1 and Type 2



37

THE MANY FACES OF A 7% A1C

(and an average blood glucose of 154 mg/dl)



38

Actual Patients



39

Moderate NPDR Review

At least one hemorrhage or MA and at least one of the following

- Hard exudate
- Cotton wool spots
- Venous beading

27% risk of progressing to proliferative DR in 1 year

- AOA Clinical Practice Guidelines

40



41

Severe NPDR

- 4-2-1 Rule - meets any of the following (what about 2?)
 - Severe intraretinal hemorrhages in 4 quadrants
 - Venous beading in 2 or more quadrants
 - IRMA in one or more quadrants

Greater than 50% chance of converting to proliferative DR in 1 year


- AOA Clinical Practice Guidelines
- And...consult with an ophthalmologist

42

43


AAO 2025 Guidelines

- "Using OCTA, preclinical microvascular changes can be detected, regions of macular nonperfusion can be quantified (studies have shown that nonperfusion correlates to severity of DR), and retinal neovascular tissue can be identified."




Continuing Education
1.0 CME/ANNUAL CME

Protecting Sight. Strengthening Lives.



Diabetic Retinopathy
Preferred Practice
Pattern¹


44



45


AAO 2025 Guidelines

- "Electroretinography is also being used to evaluate neural dysfunction of the retina even in eyes without apparent retinal vascular abnormalities, and it could help to predict the location of future microaneurysms."




The graphic on the right side of the slide features a large green circle with the text "Diabetic Retinopathy Preferred Practice Pattern®" inside it. Above the circle is a small purple circular logo with a white star and the text "AMERICAN ACADEMY OF OPTOMETRIC OPTICIANS". To the right of the logo is the text "Protecting Sight. Empowering Lives.®". Below the green circle is a grey semi-circle.

46



47





OD CODER

@ODCoder · 125 subscribers · 10 videos

This channel deals with all things billing and coding. It will help navigate the rough waters...more



[Customize channel](#)
[Manage videos](#)





YouTube


48

OD Coder  

Fundus Photography 92250

- \$35.98
- Written order and interpretation
- Bilateral
 - Unilateral RT or LT with 52 modifier (reduced services)
- Not a substitute for a dilated exam
- “if the study is performed as a screening, it is not covered by medicare”
- Mutually exclusive with OCT nerve/macula – 59 modifier
- **Now covered with E11.9**

Glare sensitivity H53.71
Retinal ischemia H35.82
Visual discomfort H53.143
Visual distortions of shape and size H53.15




49

OD Coder Update

92137 OCT Angiography

- Jan 1
- Both traditional mac OCT 92134 and OCT-A 92137 must be performed and interpreted the same day
- Cannot be billed with 92133 or separately with 92134
- National Average
 - o 92134 \$31
 - o 92137 \$57
- Any codes that are reimbursable with 92134
- No glaucoma codes



50

OD Coder  

92273 Full field electroretinogram for diabetes

92274 Multifocal electroretinogram

- \$118.32
- Written order, Interpretation and report
- Any diabetic retinopathy code
- Changes in retinal vascular appearance H35.011-013
- Hypertensive retinopathy H35.031-033
- Retinal ischemia H35.82



51


Macular Thickness in DR

300-400 microns?

Over 400 microns – automatic referral


52

Examples



53

Which is worse for diabetic retinopathy, blood glucose levels that are too high or too low?



54

Blood sugar limbo may exacerbate retinopathy

- “Our results show that these periodic low glucose levels cause an increase in certain retinal cell proteins, resulting in an overgrowth of blood vessels and worsening diabetic eye disease,”
- Akrit Sodhi, MD, PhD; Channayya Guo; Monika Deshpande; Yuezhi Niu; Isha Kachwala; Haley Mignatt; Taylor Neuse; Sushant Balagopal; Parthiv Patel; Michael Romalis; Aaron Sanchez; Neelam Inamdar; Thomas V. Johnson; Miguel Flores-Bellver; Maria Valeria Carro-Solís; Silvia Montanari; HIF-1α accumulation in response to transient hypoglycemia may worsen diabetic eye disease. Cell Reports. Published January 2023. DOI: <https://doi.org/10.1016/j.celrep.2022.111309>.



55

What about GLP-1's?

Glucagon-like peptide

- Hormone released when food is eaten to slow gastric emptying
- Increases insulin release
- Controls the feeling of satiety after eating

Options

- Trulicity
- Ozempic
- Rybelsis
- Mounjaro


56



57

In the Management of Diabetic Retinopathy

- When is the right time to refer to retina?
 - Advanced diagnostics like OCT-A and ERG can help



58

Physical activity = lower risk of Diabetic Retinopathy

- In Type 1
 - Along with lipid levels
- In Type 2
 - Impact is more pronounced in **vision threatening DR**
 - Improves lipid profile, BMI and blood pressure

Ben C. Liu M, Li J, Gao Y, Hu J, Lu P. Physical activity and risk of diabetic retinopathy: a systematic review and meta-analysis. Acta diabetologica. 2020 Aug 1;56:823-37.



59

Diabetic Retinopathy Exercise Tips

- Prioritize blood sugar control
 - Monitor levels, increase gradually to reduce BS dips
- Proper footwear
 - Peripheral neuropathy issues – custom fitting
- Cardio and Strength training
 - Yoga and Tai Chi
- Use caution within 1 week of intravitreal injections
 - Slightly increased risk of vitreous hemorrhage, endophthalmitis





60

Case

- 80 Y/O W/F
- Dx with AMD 2013
- Used AREDS/AREDS2 "off and on"
- 6 months ago Adapt Dx Rod Intercept 13.2

61

Optomaps



62



And now...

- 6 months ago, began new supplement, reports excellent compliance
- Begins a consistent walking program
- Adapt Dx 12.1 (Baseline 13.2)



63



Cross Line Comparison Report


64

65


2 AMD supplements prior to Intermediate Stage



Numacula Omega (PRN)

The AREDS 30 study supports Numacula omega 3 by showing a **30% reduced risk of developing both CGA and wet form AMD over the 12-year study.**

SanGiovanni, John Paul, et al. "n-3 Long-Chain Polyunsaturated Fatty Acid Intake and 12-Yr Incidence of Neovascular Age-Related Macular Degeneration and Central Geographic Atrophy: AREDS Report 30, a Prospective Cohort Study from the Age-Related Eye Disease Study." The American Journal of Clinical Nutrition, vol. 90, no. 6, 7 Oct. 2009, pp. 1605-1607.



Macuhealth

Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in **significant increases in macular pigment and improvements in contrast sensitivity, glare disability, and photostress recovery.**

Akufu, Kwabena Owusu, et al. "Relationship between macular pigment and visual function in subjects with early age-related macular degeneration." British Journal of Ophthalmology 80, 2 (2007), 190-197.

66


OD Coder  

- **Computer ophthalmic imaging posterior segment 92134**
- \$37.80
- Written order and report
- Bilateral
 - Unilateral RT or LT with 52 modifier (reduced services)
- Once every 2 months
- Pathologies
 - Hundreds
 - Visual distortion of shape and size* H53.15
 - Scotomas and visual field defects H53.411-.483
 - Retinal ischemia H35.82
 - Degenerative myopia H44.2E1-.2E3
 - Other long-term drug treatment Z79.899 (baseline and annually)
- Mutually exclusive with 92250**




67

AMD Staging



Mild AMD characterized by medium-sized drusen (63µm to 125µm)



Intermediate AMD demonstrating large-sized drusen (>125µm)

- **Category 1:** Early AMD characterized by fewer than five small drusen, each below 63µm in size.
- **Category 2:** Mild AMD defined as multiple small drusen, a single intermediate-sized drusen from 63µm to 124µm or RPE changes.
- **Category 3:** Moderate AMD characterized by one large drusen greater than 125µm, extensive intermediate drusen or GA non-centrally.
- **Category 4:** Advanced AMD defined as more than one large drusen or GA centrally.

Age-Related Eye Disease Study Research Group. The AREDS system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001;132(5):668-81.

68

Case

88 Y/O W/M

Here for AMD exam, last visit 1 year ago


OcHx: Mild nonexudative AMD, hypertensive retinopathy, macular pucker OD

Not taking his supplements (macuhealth), reports little to no exercise


69

Retina Map Change Analysis

Full Retina Thickness Map



70



71



Reclassify?

- Intermediate AMD
 - ARED2
 - Omega-3?
 - Exercise?

72

Type 1 "Occult" CNV



- New vessels develop in the choroid
- New vessels located **BELOW** RPE and ABOVE Bruch's membrane



73

Type 2 "Classic" CNV

- New vessels develop in choroid
- New vessels located **ABOVE** the RPE and ABOVE Bruch's membrane



74

Case


72 Y/O W/M

"VISION IN THE LEFT EYE IS NOT AS BRIGHT AS THE RIGHT EYE"


BCVA 20/25 OD AND 20/30 OS

PREVIOUS EXAM 9 MONTHS AGO – DX WITH MILD DRY AMD OU


75

Fundus
Photos


76




77

OS OCT
Cross Section


78




79




80




81




82




83



84



85



86

Case


67 Y/O W/M

Here for comprehensive exam complaining of occasional floaters

BP 130/91 RAS, "white coat syndrome"

Low risk glaucoma suspect based on large cupping

87



88





89

Diagnosis


- Hypertensive Retinopathy
 - Performed same day OCT-A
- Plan
 - Return for OCT-A and ERG

90




Hypertensive Retinopathy

- Signs
 - constricted and tortuous arterioles
 - retinal hemorrhage
 - hard exudates
 - cotton wool spots
 - Nerve edema
 - widening of the arteriole reflex
 - arteriovenous crossing signs
 - copper or silver wire arterioles




See the signs

- Salus sign – deflection of the vein
- Gunn's sign – tapering of vein at the crossing
- Bonnet's sign – banking of the distal vein to the crossing




The image displays three vertical panels, each illustrating a different venous sign on a reddish-brown background. The first panel, labeled 'SALUS SIGN', shows a blue line representing a vein that curves upwards and to the right. The second panel, labeled 'GUNN'S SIGN', shows a blue line representing a vein that tapers as it approaches a horizontal brown line representing a crossing. The third panel, labeled 'BONNET SIGN', shows a blue line representing a vein that curves sharply upwards and to the right, banking around a horizontal brown line representing a crossing.



Salus sign

Gunn's Sign



97

Underdiagnosis of Hypertensive Retinopathy

- Low Sensitivity of Detection Methods
 - Sensitivity of detecting HR ranged from **3% to 21%**
 - van den Born BJ, Hulsman CA, Hoeksma JB, Schlingemann RO, van Montfrans GA. Value of routine funduscopy in patients with hypertension: systematic review. *BMJ*. 2005 Jul 9;331(7508):73.
- High Prevalence Yet Limited Recognition
 - **44%** of referred hypertensive patients **had undiagnosed HR**
 - including HR in the assessment of end-organ damage increased the number of patients requiring treatment from **3% to 14%**
 - HR is often overlooked in treatment decisions
 - Kolman SA, van Sijl AM, van der Sluis FA, van de Ree MA. Consideration of hypertensive retinopathy as an important end-organ damage in patients with hypertension. *J Hum Hypertens*. 2017 Feb;31(2):121-125.
- Diagnostic Challenges and Variability
 - High interobserver (**20% to 40%**) and intraobserver (**10% to 33%**) variability
 - Schmieder RE. Hypertensive retinopathy: a window to vascular remodeling in arterial hypertension. *Hypertension*. 2008 Jan 1;51(1):43-4.

98

Summary

Your patients are counting on us to help manage the 3 most common retinal diseases

Improving and refining management protocol leads to better patient care

Our patients deserve it

99

Thank You!!!

mcymbor@nittanyeye.com

MIKECYMBOR.COM

100